Genmab A/S (NASDAQ:GMAB) Hits New 1-Year High – What’s Next?

Genmab A/S Sponsored ADR (NASDAQ:GMAB)’s share price reached a new 52-week high on Tuesday. The stock traded as high as $35.70 and last traded at $35.36, with a volume of 2794569 shares traded. The stock had previously closed at $35.32.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Guggenheim boosted their price target on shares of Genmab A/S from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 7th. New Street Research set a $43.00 price objective on shares of Genmab A/S in a research note on Wednesday, July 22nd. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, September 1st. TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and boosted their target price for the company from $32.00 to $43.00 in a research note on Wednesday, July 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Genmab A/S in a report on Monday, September 14th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Genmab A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.50.

Genmab A/S Trading Up 0.3%

The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. The company has a market cap of $22.26 billion, a PE ratio of 28.09, a P/E/G ratio of 1.93 and a beta of 0.84. The business’s 50-day simple moving average is $32.54 and its 200-day simple moving average is $28.86.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.12 billion. As a group, analysts expect that Genmab A/S Sponsored ADR will post 1.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GMAB. QRG Capital Management Inc. raised its stake in shares of Genmab A/S by 10.4% during the 2nd quarter. QRG Capital Management Inc. now owns 72,643 shares of the company’s stock worth $1,996,000 after purchasing an additional 6,821 shares in the last quarter. WINTON GROUP Ltd grew its stake in shares of Genmab A/S by 158.9% in the 2nd quarter. WINTON GROUP Ltd now owns 40,900 shares of the company’s stock valued at $1,124,000 after buying an additional 25,100 shares in the last quarter. Engineers Gate Manager LP acquired a new position in Genmab A/S in the second quarter worth approximately $360,000. Integrated Wealth Concepts LLC acquired a new position in Genmab A/S in the second quarter worth approximately $31,000. Finally, Nykredit A S bought a new position in Genmab A/S during the second quarter valued at approximately $58,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates.